Astrocytic factor slows wholebody aging in mice study
Increasing fibroblast growth factor 13 (FGF13) in astrocytes means an astrocytic factor slows wholebody aging in mice: treated older animals scored closer to young mice on memory tests, with less bloodstream inflammation and less senescence in skin, liver, spleen, and kidney, Aging Cell work shows.
Key Takeaways
- Raising FGF13 only in astrocytes improved cognition and cut systemic inflammation in older mice.
- Knocking out FGF13 in astrocytes worsened maze performance and raised senescence in multiple organs.
- FGF13 binds Phafin2 and appears to boost autophagy, a cellular cleanup process that declines with age.
- Researchers say human relevance is unproven; no clinical delivery method was proposed.
What did the Aging Cell study actually find?
As reported by Lifespan.io, scientists showed that FGF13 normally falls with age in non-neuronal brain cells, including astrocytes. When they boosted FGF13 specifically in astrocytes of older mice, the animals performed similarly to young mice on the Morris water maze and did better on related spatial tests than untreated aged peers.
The same brain-only tweak lowered circulating inflammatory cytokines—especially IFN-γ and IL-6—and modestly reduced senescence markers in skin, liver, spleen, and kidney, though not in the heart. It also blunted age-related weight gain. That mix of brain and body effects is why coverage frames this as an longevity and biohacking lead: one cell type may broadcast aging signals through the blood.
Why would astrocytes affect aging outside the brain?
The reverse experiment helps answer that. Removing FGF13 from astrocytes made aged mice worse on the water maze than aged controls. Those animals also showed more cellular senescence in heart, skin, liver, spleen, and kidney, plus higher circulating inflammatory cytokines—despite a knockout limited to astrocytes.
The authors concluded the brain was amplifying and transmitting aging signals to other tissues via the blood. In cell culture, FGF13-deficient astrocytes raised complement protein C3 and Cx43, impaired neuronal synapses, and pushed microglia to release inflammatory factors; overexpression moved those readouts in the beneficial direction.
How might FGF13 slow aging at the molecular level?
FGF13 is a non-secreted member of the fibroblast growth factor family and does not act through classic FGF receptors the way secreted cousins such as FGF21 do. RNA sequencing of overexpressing astrocytes found hundreds of genes shifted across lysosomal transport, inflammation, metabolism, and signaling pathways.
Mechanistically, FGF13 physically interacts with Phafin2, an autophagy-related protein that also declines with age. Raising FGF13 raised Phafin2, and brains from overexpressing mice showed more autophagosomes, autolysosomes, and autophagy markers P62 and LC3. Public mouse data, with supportive macaque patterns, steered the team toward astrocytes as the key cell type.
The paper does not offer a drug or gene therapy plan for people. Further work would need to confirm results in non-human primates before any human translation. For now, the credible buzz is narrower: dialing up one astrocytic factor slowed whole-body aging signatures in mice while restoring much of their cognitive edge.